Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/16598
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Thomas, D | - |
dc.contributor.author | Abramson, Michael J | - |
dc.contributor.author | Bonevski, B | - |
dc.contributor.author | Taylor, Simone E | - |
dc.contributor.author | Poole, SG | - |
dc.contributor.author | Paul, E | - |
dc.contributor.author | Weeks, GR | - |
dc.contributor.author | Dooley, MJ | - |
dc.contributor.author | George, J | - |
dc.date | 2016-01-13 | - |
dc.date.accessioned | 2017-03-09T00:54:46Z | - |
dc.date.available | 2017-03-09T00:54:46Z | - |
dc.date.issued | 2016-04 | - |
dc.identifier.citation | Addiction 2016; 111(4): 714-723 | en_US |
dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/16598 | - |
dc.description.abstract | AIMS: To evaluate the effectiveness of a pharmacist-led multi-component smoking cessation programme (GIVE UP FOR GOOD) compared with usual care in hospitalized smokers. DESIGN: Randomized, assessor-blinded, parallel-group trial. SETTING: Three tertiary public hospitals in Australia. PARTICIPANTS: A total of 600 adult in-patient smokers [mean ± standard deviation (SD), age 51 ± 14 years; 64% male] available for 12 months follow-up. INTERVENTIONS: Multi-component hospital pharmacist-led behavioural counselling and/or pharmacotherapy provided during hospital stay, on discharge and 1 month post-discharge, with further support involving community health professionals (n = 300). Usual care comprised routine care provided by hospitals (n = 300). MEASUREMENTS: Two primary end-points were tested using intention-to-treat analysis: carbon monoxide (CO)-validated 1-month sustained abstinence at 6-month follow-up and verified 6-month sustained abstinence at 12-month follow-up. Smoking status and pharmacotherapy usage were assessed at baseline, discharge, 1, 6 and 12 months. FINDINGS: Sustained abstinence rates for intervention and control groups were not significantly different at both 6 months [11.6% (34 of 294) versus 12.6% (37 of 294); odds ratio (OR) = 0.91, 95% confidence interval (CI) = 0.55-1.50] and 12 months [11.6% (34 of 292) versus 11.2% (33 of 294); OR = 1.04, 95% CI = 0.63-1.73]. Secondary end-points, self-reported continuous abstinence at 6 and 12 months, also agreed with the primary end-points. Use of pharmacotherapy was higher in the intervention group, both during hospital stay [52.3% (157 of 300) versus 42.7% (128 of 300); P = 0.016] and after discharge [59.6% (174 of 292) versus 43.5% (128 of 294); P < 0.001]. CONCLUSIONS: A pharmacist-led multi-component smoking cessation intervention provided during hospital stay did not improve sustained abstinence rates at either 6 or 12 months compared with routine hospital care. | en_US |
dc.subject | Hospitals | en_US |
dc.subject | Pharmacists | en_US |
dc.subject | Randomized controlled trial | en_US |
dc.subject | Smoking cessation | en_US |
dc.title | Integrating smoking cessation into routine care in hospitals—a randomized controlled trial | en_US |
dc.type | Journal Article | en_US |
dc.identifier.journaltitle | Addiction | en_US |
dc.identifier.affiliation | Centre for Medicine Use and Safety, Monash University, Melbourne, Victoria, Australia | en_US |
dc.identifier.affiliation | Department of Epidemiology and Preventive Medicine, Monash University, The Alfred, Melbourne, Victoria, Australia | en_US |
dc.identifier.affiliation | School of Medicine and Public Health, University of Newcastle, Callaghan, New South Wales, Australia | en_US |
dc.identifier.affiliation | Pharmacy Department, Austin Health, Heidelberg, Victoria, Australia | en_US |
dc.identifier.affiliation | Pharmacy Department, Alfred Health, Melbourne, Victoria, Australia | en_US |
dc.identifier.affiliation | Clinical Haematology Department, The Alfred, Melbourne, Victoria, Australia | en_US |
dc.identifier.affiliation | Pharmacy Department, Barwon Health, Geelong, Victoria, Australia | en_US |
dc.type.studyortrial | Randomized Controlled Clinical Trial/Controlled Clinical Trial | en_US |
dc.identifier.pubmeduri | https://pubmed.ncbi.nlm.nih.gov/26597421 | en_US |
dc.identifier.doi | 10.1111/add.13239 | en_US |
dc.type.content | Text | en_US |
dc.type.austin | Journal Article | en_US |
local.name.researcher | Taylor, Simone E | |
item.grantfulltext | none | - |
item.openairetype | Journal Article | - |
item.fulltext | No Fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.cerifentitytype | Publications | - |
crisitem.author.dept | Pharmacy | - |
Appears in Collections: | Journal articles |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.